Back to Search Results

Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: post hoc analysis.

Hospital General Universitario de Alicante, Alicante, 03010, Spain. University of Rome Tor Vergata, Department of Clinical Science & Translational Medicine & Unit of Pain Therapy, Polyclinic of Tor Vergata, Rome, 00133, Italy. Hospital Universitario 12 de Octubre; Department of Rehabilitation, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain. Italian College of General Practitioners & Primary Care, Florence, 50141, Italy. Hospital Universitario Fundación Santa Fe, Bogotá 110121, Universidad de los Andes, Colombia. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico. Global Market Access, Grünenthal GmbH, Aachen, 52099, Germany. R&D - Development - Data Sciences, Grünenthal GmbH, Aachen, 52099, Germany. Global Medical Affairs, Grünenthal GmbH, Aachen, 52099, Germany.

Pain management. 2021;(2):173-187
Full text from:

Other resources

Abstract

Aims: To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. Patients & methods: Post hoc analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. Results: All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Conclusion: Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.

Methodological quality

Metadata